Table 2.
Baseline Characteristics of Matched Patients
| No Sleep‐Disordered Breathing (n=88) | Sleep‐Disordered Breathing (n=88) | |
|---|---|---|
| Age, y | 63±12 | 63±13 |
| Male, n (%) | 66 (75) | 69 (78) |
| Body mass index, kg/m2 | 24.4±3.5 | 24.7±3.8 |
| Hypertension, n (%) | 54 (61) | 51 (58) |
| Dyslipidemia, n (%) | 39 (44) | 40 (46) |
| Diabetes mellitus, n (%) | 29 (33) | 26 (30) |
| Current smokers, n (%) | 39 (44) | 41 (47) |
| Previous myocardial infarction, n (%) | 5 (6) | 7 (8) |
| Estimated glomerular filtration rate, mL/min/1.73 m2 | 77.1 (28.6) | 74.3 (30.6) |
| Type of acute coronary syndrome, n (%) | ||
| Unstable angina pectoris | 13 (15) | 13 (15) |
| Non–ST‐segment elevation myocardial infarction | 10 (11) | 9 (10) |
| ST‐segment elevation myocardial infarction | 65 (74) | 66 (75) |
| Culprit lesion, n (%) | ||
| Right coronary artery | 37 (42) | 38 (43) |
| Left circumflex artery | 11 (13) | 14 (16) |
| Left anterior descending artery | 40 (45) | 36 (41) |
| Thrombolysis in Myocardial Infarction flow before percutaneous coronary intervention, n (%) | ||
| 0 | 57 (65) | 59 (67) |
| 1 | 8 (9) | 6 (7) |
| 2 | 10 (11) | 8 (9) |
| 3 | 13 (15) | 15 (17) |
| Thrombolysis in Myocardial Infarction flow after percutaneous coronary intervention, n (%) | ||
| 2 | 4 (5) | 6 (7) |
| 3 | 84 (95) | 82 (93) |
| Peak creatine kinase, mg/dL | 1475 (1953) | 1790 (2706) |
| Left ventricular ejection fraction, % | 57±10 | 56±12 |
| Medications, n (%) | ||
| Dual antiplatelet therapy | 81 (92) | 79 (90) |
| Angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers | 76 (86) | 74 (84) |
| β‐Blockers | 45 (51) | 45 (51) |
| Calcium channel blockers | 21 (24) | 22 (25) |
| Statins | 49 (56) | 51 (58) |
| Oral hypoglycemic agents | 12 (14) | 10 (11) |
| Insulin injection | 1 (1) | 1 (1) |
Data are presented as mean±SD or median (interquartile range) for continuous variables or number of patients (percentage) for categorical variables.